Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Goldman Sachs to hold a virtual conference » 04:55
06/10/21
06/10
04:55
06/10/21
04:55
ALNY

Alnylam

$157.41 /

+6.49 (+4.30%)

, FOLD

Amicus

$10.57 /

+0.19 (+1.83%)

, BTAI

BioXcel Therapeutics

$38.91 /

+0.97 (+2.56%)

, TXG

10x Genomics

$185.82 /

-1.29 (-0.69%)

, RPRX

Royalty Pharma

$45.99 /

-0.455 (-0.98%)

, TCDA

Tricida

$4.88 /

+0.16 (+3.39%)

, NEO

NeoGenomics

$42.62 /

+0.72 (+1.72%)

, VIR

Vir Biotechnology

$46.51 /

-0.03 (-0.06%)

, KRON

Kronos Bio

$26.78 /

-0.66 (-2.41%)

, BVS

Bioventus

$17.54 /

+0.42 (+2.45%)

, BHVN

Biohaven Pharmaceutical

$97.57 /

+2.34 (+2.46%)

, RXRX

Recursion Pharmaceuticals

$30.20 /

+0.46 (+1.55%)

, EXEL

Exelixis

$22.78 /

+0.575 (+2.59%)

, DSGN

Design Therapeutics

$27.48 /

-0.02 (-0.07%)

, ARNA

Arena Pharmaceuticals

$62.27 /

+1.3 (+2.13%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference 2021 to be held on June 8-10.

ShowHide Related Items >><<
VIR Vir Biotechnology
$46.51 /

-0.03 (-0.06%)

TXG 10x Genomics
$185.82 /

-1.29 (-0.69%)

TCDA Tricida
$4.88 /

+0.16 (+3.39%)

RXRX Recursion Pharmaceuticals
$30.20 /

+0.46 (+1.55%)

RPRX Royalty Pharma
$45.99 /

-0.455 (-0.98%)

NEO NeoGenomics
$42.62 /

+0.72 (+1.72%)

KRON Kronos Bio
$26.78 /

-0.66 (-2.41%)

FOLD Amicus
$10.57 /

+0.19 (+1.83%)

EXEL Exelixis
$22.78 /

+0.575 (+2.59%)

BVS Bioventus
$17.54 /

+0.42 (+2.45%)

BTAI BioXcel Therapeutics
$38.91 /

+0.97 (+2.56%)

BHVN Biohaven Pharmaceutical
$97.57 /

+2.34 (+2.46%)

ARNA Arena Pharmaceuticals
$62.27 /

+1.3 (+2.13%)

ALNY Alnylam
$157.41 /

+6.49 (+4.30%)

ALNY Alnylam
$157.41 /

+6.49 (+4.30%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
FOLD Amicus
$10.57 /

+0.19 (+1.83%)

05/27/21 Needham
Amicus initiated with a Hold at Needham
05/27/21 Needham
Amicus initiated with a Hold at Needham
05/20/21 UBS
Amicus initiated with a Buy at UBS
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
BTAI BioXcel Therapeutics
$38.91 /

+0.97 (+2.56%)

06/01/21 H.C. Wainwright
BioXcel Therapeutics price target raised to $176 from $170 at H.C. Wainwright
05/11/21 H.C. Wainwright
BioXcel Therapeutics price target lowered to $170 from $175 at H.C. Wainwright
04/09/21 Berenberg
BioXcel Therapeutics initiated with a Buy at Berenberg
04/01/21 Truist
BioXcel Therapeutics price target lowered to $127 from $150 at Truist
TXG 10x Genomics
$185.82 /

-1.29 (-0.69%)

03/15/21
Fly Intel: Top five analyst initiations
03/15/21 William Blair
10x Genomics initiated with an Outperform at William Blair
02/18/21 Cowen
10x Genomics price target raised to $200 from $155 at Cowen
02/18/21 JPMorgan
10x Genomics price target raised to $195 from $160 at JPMorgan
RPRX Royalty Pharma
$45.99 /

-0.455 (-0.98%)

06/03/21 SVB Leerink
MorphoSys upgraded to Outperform at SVB Leerink
11/09/20
Fly Intel: Top five analyst upgrades
11/09/20 UBS
Royalty Pharma upgraded to Buy from Neutral at UBS
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
TCDA Tricida
$4.88 /

+0.16 (+3.39%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
NEO NeoGenomics
$42.62 /

+0.72 (+1.72%)

06/03/21 Goldman Sachs
NeoGenomics initiated with a Buy at Goldman Sachs
05/25/21 Truist
NeoGenomics price target lowered to $54 from $65 at Truist
02/25/21 Craig-Hallum
NeoGenomics price target raised to $65 from $50 at Craig-Hallum
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform on valuation at Raymond James
VIR Vir Biotechnology
$46.51 /

-0.03 (-0.06%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
KRON Kronos Bio
$26.78 /

-0.66 (-2.41%)

11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Jefferies
Kronos Bio initiated with a Buy at Jefferies
11/03/20 Piper Sandler
Kronos Bio initiated with an Overweight at Piper Sandler
11/03/20 Goldman Sachs
Kronos Bio initiated with a Buy at Goldman Sachs
BVS Bioventus
$17.54 /

+0.42 (+2.45%)

03/08/21 Canaccord
Canaccord starts 'medtech execution story' Bioventus with Buy
03/08/21 JPMorgan
Bioventus initiated with an Overweight at JPMorgan
03/08/21 Morgan Stanley
Bioventus initiated with an Overweight at Morgan Stanley
03/08/21 Canaccord
Bioventus initiated with a Buy at Canaccord
BHVN Biohaven Pharmaceutical
$97.57 /

+2.34 (+2.46%)

06/01/21 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $140 from $125 at Cantor Fitzgerald
05/28/21 Mizuho
Biohaven approval should lift 'important overhang,' says Mizuho
05/19/21 Piper Sandler
Piper 'incrementally bullish' on Biohaven, AbbVie migraine drugs
05/12/21 SVB Leerink
Biohaven Pharmaceutical price target lowered to $105 from $115 at SVB Leerink
RXRX Recursion Pharmaceuticals
$30.20 /

+0.46 (+1.55%)

05/11/21
Fly Intel: Top five analyst initiations
05/11/21 SVB Leerink
SVB Leerink bullish on Recursion Pharmaceuticals, initiates with an Outperform
05/11/21 BofA
BofA starts Recursion Pharmaceuticals at Buy with $31 price target
05/11/21 SVB Leerink
Recursion Pharmaceuticals initiated with an Outperform at SVB Leerink
EXEL Exelixis
$22.78 /

+0.575 (+2.59%)

05/25/21 Stifel
Exelixis' COSMIC-021 cohort 6 results 'incrementally negative,' says Stifel
05/18/21 Goldman Sachs
Exelixis assumed with a Sell at Goldman Sachs
03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
DSGN Design Therapeutics
$27.48 /

-0.02 (-0.07%)

05/19/21 Piper Sandler
Reata news should be good for Design Therapeutics, says Piper Sandler
04/20/21 SVB Leerink
SVB Leerink bullish on Design Therapeutics, initiates with an Outperform
04/20/21 SVB Leerink
Design Therapeutics initiated with an Outperform at SVB Leerink
04/20/21 Piper Sandler
Design Therapeutics initiated with an Overweight at Piper Sandler
ARNA Arena Pharmaceuticals
$62.27 /

+1.3 (+2.13%)

05/18/21 Goldman Sachs
Arena Pharmaceuticals initiated with a Buy at Goldman Sachs
04/27/21 Citi
Arena Pharmaceuticals initiated with a Buy at Citi
04/26/21 Credit Suisse
Arena Pharmaceuticals assumed with an Outperform at Credit Suisse
04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
TXG 10x Genomics
$185.82 /

-1.29 (-0.69%)

TCDA Tricida
$4.88 /

+0.16 (+3.39%)

RPRX Royalty Pharma
$45.99 /

-0.455 (-0.98%)

NEO NeoGenomics
$42.62 /

+0.72 (+1.72%)

KRON Kronos Bio
$26.78 /

-0.66 (-2.41%)

FOLD Amicus
$10.57 /

+0.19 (+1.83%)

EXEL Exelixis
$22.78 /

+0.575 (+2.59%)

DSGN Design Therapeutics
$27.48 /

-0.02 (-0.07%)

BVS Bioventus
$17.54 /

+0.42 (+2.45%)

BTAI BioXcel Therapeutics
$38.91 /

+0.97 (+2.56%)

BHVN Biohaven Pharmaceutical
$97.57 /

+2.34 (+2.46%)

ARNA Arena Pharmaceuticals
$62.27 /

+1.3 (+2.13%)

ALNY Alnylam
$157.41 /

+6.49 (+4.30%)

  • 16
    Apr
  • 26
    Mar
  • 16
    Mar
  • 11
    Feb
  • 07
    Jan
  • 16
    Oct
  • 09
    Oct
  • 11
    Sep
  • 29
    Jul
  • 08
    Jul
  • 16
    Jun
FOLD Amicus
$10.57 /

+0.19 (+1.83%)

VIR Vir Biotechnology
$46.51 /

-0.03 (-0.06%)

TCDA Tricida
$4.88 /

+0.16 (+3.39%)

RXRX Recursion Pharmaceuticals
$30.20 /

+0.46 (+1.55%)

NEO NeoGenomics
$42.62 /

+0.72 (+1.72%)

FOLD Amicus
$10.57 /

+0.19 (+1.83%)

EXEL Exelixis
$22.78 /

+0.575 (+2.59%)

DSGN Design Therapeutics
$27.48 /

-0.02 (-0.07%)

BVS Bioventus
$17.54 /

+0.42 (+2.45%)

BTAI BioXcel Therapeutics
$38.91 /

+0.97 (+2.56%)

BHVN Biohaven Pharmaceutical
$97.57 /

+2.34 (+2.46%)

ARNA Arena Pharmaceuticals
$62.27 /

+1.3 (+2.13%)

RXRX Recursion Pharmaceuticals
$30.20 /

+0.46 (+1.55%)

KRON Kronos Bio
$26.78 /

-0.66 (-2.41%)

FOLD Amicus
$10.57 /

+0.19 (+1.83%)

Conference/Events
Goldman Sachs to hold a virtual conference » 11:22
06/09/21
06/09
11:22
06/09/21
11:22
ALNY

Alnylam

$155.41 /

+4.49 (+2.98%)

, FOLD

Amicus

$10.64 /

+0.26 (+2.50%)

, BTAI

BioXcel Therapeutics

$38.75 /

+0.81 (+2.13%)

, TXG

10x Genomics

$188.69 /

+1.58 (+0.84%)

, RPRX

Royalty Pharma

$46.36 /

-0.085 (-0.18%)

, TCDA

Tricida

$4.99 /

+0.27 (+5.72%)

, NEO

NeoGenomics

$42.86 /

+0.96 (+2.29%)

, VIR

Vir Biotechnology

$46.90 /

+0.36 (+0.77%)

, KRON

Kronos Bio

$27.57 /

+0.13 (+0.47%)

, BVS

Bioventus

$17.62 /

+0.5 (+2.92%)

, BHVN

Biohaven Pharmaceutical

$95.97 /

+0.74 (+0.78%)

, RXRX

Recursion Pharmaceuticals

$30.10 /

+0.36 (+1.21%)

, EXEL

Exelixis

$22.47 /

+0.265 (+1.19%)

, DSGN

Design Therapeutics

$27.96 /

+0.46 (+1.67%)

, ARNA

Arena Pharmaceuticals

$61.87 /

+0.9 (+1.48%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference 2021 to be held on June 8-10.

ShowHide Related Items >><<
VIR Vir Biotechnology
$46.90 /

+0.36 (+0.77%)

TXG 10x Genomics
$188.69 /

+1.58 (+0.84%)

TCDA Tricida
$4.99 /

+0.27 (+5.72%)

RXRX Recursion Pharmaceuticals
$30.10 /

+0.36 (+1.21%)

RPRX Royalty Pharma
$46.36 /

-0.085 (-0.18%)

NEO NeoGenomics
$42.86 /

+0.96 (+2.29%)

KRON Kronos Bio
$27.57 /

+0.13 (+0.47%)

FOLD Amicus
$10.64 /

+0.26 (+2.50%)

EXEL Exelixis
$22.47 /

+0.265 (+1.19%)

BVS Bioventus
$17.62 /

+0.5 (+2.92%)

BTAI BioXcel Therapeutics
$38.75 /

+0.81 (+2.13%)

BHVN Biohaven Pharmaceutical
$95.97 /

+0.74 (+0.78%)

ARNA Arena Pharmaceuticals
$61.87 /

+0.9 (+1.48%)

ALNY Alnylam
$155.41 /

+4.49 (+2.98%)

ALNY Alnylam
$155.41 /

+4.49 (+2.98%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
FOLD Amicus
$10.64 /

+0.26 (+2.50%)

05/27/21 Needham
Amicus initiated with a Hold at Needham
05/27/21 Needham
Amicus initiated with a Hold at Needham
05/20/21 UBS
Amicus initiated with a Buy at UBS
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
BTAI BioXcel Therapeutics
$38.75 /

+0.81 (+2.13%)

06/01/21 H.C. Wainwright
BioXcel Therapeutics price target raised to $176 from $170 at H.C. Wainwright
05/11/21 H.C. Wainwright
BioXcel Therapeutics price target lowered to $170 from $175 at H.C. Wainwright
04/09/21 Berenberg
BioXcel Therapeutics initiated with a Buy at Berenberg
04/01/21 Truist
BioXcel Therapeutics price target lowered to $127 from $150 at Truist
TXG 10x Genomics
$188.69 /

+1.58 (+0.84%)

03/15/21
Fly Intel: Top five analyst initiations
03/15/21 William Blair
10x Genomics initiated with an Outperform at William Blair
02/18/21 Cowen
10x Genomics price target raised to $200 from $155 at Cowen
02/18/21 JPMorgan
10x Genomics price target raised to $195 from $160 at JPMorgan
RPRX Royalty Pharma
$46.36 /

-0.085 (-0.18%)

06/03/21 SVB Leerink
MorphoSys upgraded to Outperform at SVB Leerink
11/09/20
Fly Intel: Top five analyst upgrades
11/09/20 UBS
Royalty Pharma upgraded to Buy from Neutral at UBS
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
TCDA Tricida
$4.99 /

+0.27 (+5.72%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
NEO NeoGenomics
$42.86 /

+0.96 (+2.29%)

06/03/21 Goldman Sachs
NeoGenomics initiated with a Buy at Goldman Sachs
05/25/21 Truist
NeoGenomics price target lowered to $54 from $65 at Truist
02/25/21 Craig-Hallum
NeoGenomics price target raised to $65 from $50 at Craig-Hallum
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform on valuation at Raymond James
VIR Vir Biotechnology
$46.90 /

+0.36 (+0.77%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
KRON Kronos Bio
$27.57 /

+0.13 (+0.47%)

11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Jefferies
Kronos Bio initiated with a Buy at Jefferies
11/03/20 Piper Sandler
Kronos Bio initiated with an Overweight at Piper Sandler
11/03/20 Goldman Sachs
Kronos Bio initiated with a Buy at Goldman Sachs
BVS Bioventus
$17.62 /

+0.5 (+2.92%)

03/08/21 Canaccord
Canaccord starts 'medtech execution story' Bioventus with Buy
03/08/21 JPMorgan
Bioventus initiated with an Overweight at JPMorgan
03/08/21 Morgan Stanley
Bioventus initiated with an Overweight at Morgan Stanley
03/08/21 Canaccord
Bioventus initiated with a Buy at Canaccord
BHVN Biohaven Pharmaceutical
$95.97 /

+0.74 (+0.78%)

06/01/21 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $140 from $125 at Cantor Fitzgerald
05/28/21 Mizuho
Biohaven approval should lift 'important overhang,' says Mizuho
05/19/21 Piper Sandler
Piper 'incrementally bullish' on Biohaven, AbbVie migraine drugs
05/12/21 SVB Leerink
Biohaven Pharmaceutical price target lowered to $105 from $115 at SVB Leerink
RXRX Recursion Pharmaceuticals
$30.10 /

+0.36 (+1.21%)

05/11/21
Fly Intel: Top five analyst initiations
05/11/21 SVB Leerink
SVB Leerink bullish on Recursion Pharmaceuticals, initiates with an Outperform
05/11/21 BofA
BofA starts Recursion Pharmaceuticals at Buy with $31 price target
05/11/21 SVB Leerink
Recursion Pharmaceuticals initiated with an Outperform at SVB Leerink
EXEL Exelixis
$22.47 /

+0.265 (+1.19%)

05/25/21 Stifel
Exelixis' COSMIC-021 cohort 6 results 'incrementally negative,' says Stifel
05/18/21 Goldman Sachs
Exelixis assumed with a Sell at Goldman Sachs
03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
DSGN Design Therapeutics
$27.96 /

+0.46 (+1.67%)

05/19/21 Piper Sandler
Reata news should be good for Design Therapeutics, says Piper Sandler
04/20/21 SVB Leerink
SVB Leerink bullish on Design Therapeutics, initiates with an Outperform
04/20/21 SVB Leerink
Design Therapeutics initiated with an Outperform at SVB Leerink
04/20/21 Piper Sandler
Design Therapeutics initiated with an Overweight at Piper Sandler
ARNA Arena Pharmaceuticals
$61.87 /

+0.9 (+1.48%)

05/18/21 Goldman Sachs
Arena Pharmaceuticals initiated with a Buy at Goldman Sachs
04/27/21 Citi
Arena Pharmaceuticals initiated with a Buy at Citi
04/26/21 Credit Suisse
Arena Pharmaceuticals assumed with an Outperform at Credit Suisse
04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
TXG 10x Genomics
$188.69 /

+1.58 (+0.84%)

TCDA Tricida
$4.99 /

+0.27 (+5.72%)

RPRX Royalty Pharma
$46.36 /

-0.085 (-0.18%)

NEO NeoGenomics
$42.86 /

+0.96 (+2.29%)

KRON Kronos Bio
$27.57 /

+0.13 (+0.47%)

FOLD Amicus
$10.64 /

+0.26 (+2.50%)

EXEL Exelixis
$22.47 /

+0.265 (+1.19%)

DSGN Design Therapeutics
$27.96 /

+0.46 (+1.67%)

BVS Bioventus
$17.62 /

+0.5 (+2.92%)

BTAI BioXcel Therapeutics
$38.75 /

+0.81 (+2.13%)

BHVN Biohaven Pharmaceutical
$95.97 /

+0.74 (+0.78%)

ARNA Arena Pharmaceuticals
$61.87 /

+0.9 (+1.48%)

ALNY Alnylam
$155.41 /

+4.49 (+2.98%)

  • 16
    Apr
  • 26
    Mar
  • 16
    Mar
  • 11
    Feb
  • 07
    Jan
  • 16
    Oct
  • 09
    Oct
  • 11
    Sep
  • 29
    Jul
  • 08
    Jul
  • 16
    Jun
FOLD Amicus
$10.64 /

+0.26 (+2.50%)

VIR Vir Biotechnology
$46.90 /

+0.36 (+0.77%)

TCDA Tricida
$4.99 /

+0.27 (+5.72%)

RXRX Recursion Pharmaceuticals
$30.10 /

+0.36 (+1.21%)

NEO NeoGenomics
$42.86 /

+0.96 (+2.29%)

FOLD Amicus
$10.64 /

+0.26 (+2.50%)

EXEL Exelixis
$22.47 /

+0.265 (+1.19%)

DSGN Design Therapeutics
$27.96 /

+0.46 (+1.67%)

BVS Bioventus
$17.62 /

+0.5 (+2.92%)

BTAI BioXcel Therapeutics
$38.75 /

+0.81 (+2.13%)

BHVN Biohaven Pharmaceutical
$95.97 /

+0.74 (+0.78%)

ARNA Arena Pharmaceuticals
$61.87 /

+0.9 (+1.48%)

RXRX Recursion Pharmaceuticals
$30.10 /

+0.36 (+1.21%)

KRON Kronos Bio
$27.57 /

+0.13 (+0.47%)

FOLD Amicus
$10.64 /

+0.26 (+2.50%)

Upgrade
MorphoSys upgraded to Outperform at SVB Leerink » 08:26
06/03/21
06/03
08:26
06/03/21
08:26
MOR

MorphoSys

$19.20 /

-2.94 (-13.28%)

, CNST

Constellation Pharmaceuticals

$33.53 /

+13.28 (+65.58%)

, RPRX

Royalty Pharma

$42.97 /

+2.72 (+6.76%)

As previously reported,…

As previously reported, SVB Leerink analyst Geoffrey Porges upgraded MorphoSys (MOR) to Outperform from Market Perform with a price target of EUR 106, up from EUR 86, after the stock's selloff in response to its announced transactions with Constellation Pharmaceuticals (CNST) and Royalty Pharma (RPRX). The analyst regards the two transactions positively as MorphoSys is trading short-term cash for long-term opportunity, and selling an underappreciated royalty asset, and two royalty options, to acquire wholly owned development programs and a validated drug discovery platform. Additionally, most of Constellation Pharmaceuticals' opportunities are in heme malignancies, which is where MorphoSys is already focused, Porges adds, pointing out that the acquired assets are relatively high probability development programs with significant pharmacologic, clinical and commercial synergies with MorphoSys' existing commercial product, Monjuvi. Lastly, the analyst argues that investors are not being materially diluted, and the transactions allow MorphoSys to "borrow" Royalty's balance sheet and credit rating to finance its business development activity, thus effectively expanding its own balance sheet and lowering their own cost of capital.

ShowHide Related Items >><<
RPRX Royalty Pharma
$42.97 /

+2.72 (+6.76%)

MOR MorphoSys
$19.20 /

-2.94 (-13.28%)

CNST Constellation Pharmaceuticals
$33.53 /

+13.28 (+65.58%)

MOR MorphoSys
$19.20 /

-2.94 (-13.28%)

06/03/21 Bryan Garnier
MorphoSys downgraded to Neutral from Buy at Bryan Garnier
06/03/21 SVB Leerink
MorphoSys upgraded to Outperform from Market Perform at SVB Leerink
06/03/21 Bryan Garnier
MorphoSys downgraded to Neutral from Buy at Bryan Garnier
05/24/21 Morgan Stanley
Morgan Stanley upgrades MorphoSys with shares near 'bear case value'
CNST Constellation Pharmaceuticals
$33.53 /

+13.28 (+65.58%)

06/03/21 Cowen
Constellation Pharmaceuticals downgraded to Market Perform from Outperform at Cowen
06/02/21 BMO Capital
Constellation Pharmaceuticals downgraded to Market Perform at BMO Capital
06/02/21 Baird
Constellation Pharmaceuticals downgraded to Neutral from Outperform at Baird
06/02/21 JPMorgan
Constellation Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan
RPRX Royalty Pharma
$42.97 /

+2.72 (+6.76%)

11/09/20
Fly Intel: Top five analyst upgrades
11/09/20 UBS
Royalty Pharma upgraded to Buy from Neutral at UBS
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
07/13/20 Cowen
Cowen starts Royalty Pharma with Outperform, $55 price target
RPRX Royalty Pharma
$42.97 /

+2.72 (+6.76%)

CNST Constellation Pharmaceuticals
$33.53 /

+13.28 (+65.58%)

  • 16
    Oct
  • 17
    Jun
  • 16
    Jun
MOR MorphoSys
$19.20 /

-2.94 (-13.28%)

Hot Stocks
Royalty expects MorphoSys deal to add $150M to adjusted cash receipts by 2025 » 07:46
06/02/21
06/02
07:46
06/02/21
07:46
RPRX

Royalty Pharma

$40.25 /

+0.09 (+0.22%)

, MOR

MorphoSys

$22.14 /

-0.07 (-0.32%)

, CNST

Constellation Pharmaceuticals

$20.25 /

+0.43 (+2.17%)

This strategic funding…

This strategic funding partnership with MorphoSys is expected to further diversify Royalty Pharma's portfolio with long-duration and innovative therapies. Royalty Pharma expects this transaction to add at least $150 million to Adjusted Cash Receipts by 2025 from only the Tremfya royalty and the minimum $150 million draw from the Development Funding Bonds with significant upside potential from the development-stage therapies. Royalty Pharma expects to fund this transaction with existing cash on the balance sheet and to maintain significant financial capacity to deploy capital on additional value-creating opportunities. The transaction is contingent on the closing of MorphoSys' acquisition of Constellation, which is expected in the third quarter of 2021.

ShowHide Related Items >><<
RPRX Royalty Pharma
$40.25 /

+0.09 (+0.22%)

MOR MorphoSys
$22.14 /

-0.07 (-0.32%)

CNST Constellation Pharmaceuticals
$20.25 /

+0.43 (+2.17%)

RPRX Royalty Pharma
$40.25 /

+0.09 (+0.22%)

11/09/20
Fly Intel: Top five analyst upgrades
11/09/20 UBS
Royalty Pharma upgraded to Buy from Neutral at UBS
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
07/13/20 Cowen
Cowen starts Royalty Pharma with Outperform, $55 price target
MOR MorphoSys
$22.14 /

-0.07 (-0.32%)

05/24/21 Morgan Stanley
Morgan Stanley upgrades MorphoSys with shares near 'bear case value'
05/24/21 Morgan Stanley
MorphoSys upgraded to Overweight from Equal Weight at Morgan Stanley
05/21/21 JPMorgan
MorphoSys price target lowered to EUR 105 from EUR 110 at JPMorgan
04/08/21 Deutsche Bank
MorphoSys price target lowered to EUR 116 from EUR 129 at Deutsche Bank
CNST Constellation Pharmaceuticals
$20.25 /

+0.43 (+2.17%)

01/25/21 BMO Capital
Constellation Pharmaceuticals upgraded to Outperform at BMO Capital
01/25/21 BMO Capital
Constellation upgraded to Outperform from Market Perform at BMO Capital
10/30/20 JPMorgan
Constellation added to Analyst Focus List at JPMorgan
09/08/20 Oppenheimer
Constellation Pharmaceuticals downgraded to Perform at Oppenheimer
RPRX Royalty Pharma
$40.25 /

+0.09 (+0.22%)

CNST Constellation Pharmaceuticals
$20.25 /

+0.43 (+2.17%)

  • 16
    Oct
  • 17
    Jun
  • 16
    Jun
Hot Stocks
Royalty Pharma, MorphoSys announce $2.025B strategic funding partnership » 07:44
06/02/21
06/02
07:44
06/02/21
07:44
RPRX

Royalty Pharma

$40.25 /

+0.09 (+0.22%)

, MOR

MorphoSys

$22.14 /

-0.07 (-0.32%)

, CNST

Constellation Pharmaceuticals

$20.25 /

+0.43 (+2.17%)

Royalty Pharma (RPRX) and…

Royalty Pharma (RPRX) and MorphoSys AG (MOR) announced a $2.025B strategic funding partnership as part of MorphoSys' $1.7B acquisition of Constellation Pharmaceuticals (CNST). This partnership is expected to fuel the expansion of the combined company's capabilities to help enable the development and potential approvals of important cancer treatments. This funding partnership is anchored by Royalty Pharma's acquisition of MorphoSys' rights to receive future royalties on Janssen's Tremfya. Tremfya is an anti interleukin (IL)-23, approved for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis and is also in clinical development for ulcerative colitis and Crohn's disease. In 2020, Tremfya generated sales of $1.347B Royalty Pharma will also acquire the rights to receive royalties and certain milestone payments on four attractive development-stage therapies: Gantenerumab, an anti-amyloid-beta monoclonal antibody, in Phase 3 development for Alzheimer's disease by Roche. Royalty Pharma will purchase the rights to receive 60% of MorphoSys' future royalties on gantenerumab. Otilimab, a fully human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor, in Phase 3 development for rheumatoid arthritis by GlaxoSmithKline. Royalty Pharma will purchase the rights to receive 80% of MorphoSys' future royalties and 100% of its future milestones on otilimab. Pelabresib, a bromodomain and extra-terminal nhibitor for myelofibrosis, in Phase 3 development by Constellation. Royalty Pharma will purchase the rights to receive 3% of future net sales of pelabresib. CPI-0209, a second-generation enhancer of zeste homolog 2 inhibitor, in Phase 2 development for hematological malignancies and solid tumors by Constellation. Royalty Pharma will purchase the rights to receive 3% of future net sales of CPI-0209. The long-term strategic funding partnership agreement is comprised of the following terms: $1.425B upfront payment: In exchange for the rights to receive 100% of MorphoSys' future royalties on Tremfya, 80% of MorphoSys' future royalties and 100% of MorphoSys' future milestone payments on otilimab, 60% of MorphoSys' future royalties on gantenerumab, and 3% of future net sales of Constellation's clinical stage assets, Royalty Pharma will make a $1.425B upfront payment to MorphoSys, supporting its growth strategy. The proceeds will be used to support the financing of the Constellation transaction and the development of the combined pipeline. Milestone payments: Royalty Pharma will make additional payments to MorphoSys of up to $150M upon reaching certain milestones for otilimab, gantenerumab and pelabresib. $350M Development Funding Bonds: Royalty Pharma will provide MorphoSys with access to up to $350M in Development Funding Bonds, with the flexibility to draw over a one year period, with a minimum draw of $150M. Equity Investment: After completion of the transaction, Royalty Pharma will purchase $100M of ordinary shares of MorphoSys based on the average trading price of the shares over a period preceding the closing of the transaction. The investment will be subject to the required resolutions by the management board and the supervisory boar of MorphoSys, and will constitute a cash capital increase of MorphoSys under an authorization to exclude subscription rights of existing shareholders. The new shares will be listed on the Frankfurt Stock Exchange.

ShowHide Related Items >><<
RPRX Royalty Pharma
$40.25 /

+0.09 (+0.22%)

MOR MorphoSys
$22.14 /

-0.07 (-0.32%)

CNST Constellation Pharmaceuticals
$20.25 /

+0.43 (+2.17%)

RPRX Royalty Pharma
$40.25 /

+0.09 (+0.22%)

11/09/20
Fly Intel: Top five analyst upgrades
11/09/20 UBS
Royalty Pharma upgraded to Buy from Neutral at UBS
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
07/13/20 Cowen
Cowen starts Royalty Pharma with Outperform, $55 price target
MOR MorphoSys
$22.14 /

-0.07 (-0.32%)

05/24/21 Morgan Stanley
Morgan Stanley upgrades MorphoSys with shares near 'bear case value'
05/24/21 Morgan Stanley
MorphoSys upgraded to Overweight from Equal Weight at Morgan Stanley
05/21/21 JPMorgan
MorphoSys price target lowered to EUR 105 from EUR 110 at JPMorgan
04/08/21 Deutsche Bank
MorphoSys price target lowered to EUR 116 from EUR 129 at Deutsche Bank
CNST Constellation Pharmaceuticals
$20.25 /

+0.43 (+2.17%)

01/25/21 BMO Capital
Constellation Pharmaceuticals upgraded to Outperform at BMO Capital
01/25/21 BMO Capital
Constellation upgraded to Outperform from Market Perform at BMO Capital
10/30/20 JPMorgan
Constellation added to Analyst Focus List at JPMorgan
09/08/20 Oppenheimer
Constellation Pharmaceuticals downgraded to Perform at Oppenheimer
RPRX Royalty Pharma
$40.25 /

+0.09 (+0.22%)

CNST Constellation Pharmaceuticals
$20.25 /

+0.43 (+2.17%)

  • 16
    Oct
  • 17
    Jun
  • 16
    Jun
Hot Stocks
MorphoSys announces partnership with Royalty Pharma » 07:33
06/02/21
06/02
07:33
06/02/21
07:33
MOR

MorphoSys

$22.14 /

-0.07 (-0.32%)

, RPRX

Royalty Pharma

$40.25 /

+0.09 (+0.22%)

, CNST

Constellation Pharmaceuticals

$20.25 /

+0.43 (+2.17%)

MorphoSys (MOR) announced…

MorphoSys (MOR) announced that it has entered into a long-term strategic funding partnership with Royalty Pharma (RPRX). The terms of the agreement between MorphoSys and Royalty Pharma provide for the following, under certain conditions and upon closing of the transaction with Constellation (CNST): Royalty Pharma will make a $1.425B upfront payment to MorphoSys, supporting its growth strategy. The proceeds will be used to support the financing of the Constellation transaction and development of the combined pipeline; Royalty Pharma will provide MorphoSys with access to up to $350M in Development Funding Bonds with the flexibility to draw over a one-year period; Royalty Pharma will make additional payments of up to $150M to MorphoSys upon reaching clinical, regulatory and commercial milestones for otilimab, gantenerumab and pelabresib; Royalty Pharma will have the rights to receive 100% of MorphoSys' royalties on net sales of Tremfya, 80% of future royalties and 100% of future milestone payments on otilimab, 60% of future royalties on gantenerumab, and 3% on future net sales of Constellation's clinical stage assets; and after completion of the transaction and subject to the required approvals of the management board and the supervisory board of MorphoSys, Royalty Pharma is expected to invest $100M in a cash capital increase of MorphoSys under an authorization to exclude subscription rights of existing shareholders. The new MorphoSys shares will be listed on the Frankfurt Stock Exchange.

ShowHide Related Items >><<
RPRX Royalty Pharma
$40.25 /

+0.09 (+0.22%)

MOR MorphoSys
$22.14 /

-0.07 (-0.32%)

CNST Constellation Pharmaceuticals
$20.25 /

+0.43 (+2.17%)

MOR MorphoSys
$22.14 /

-0.07 (-0.32%)

05/24/21 Morgan Stanley
Morgan Stanley upgrades MorphoSys with shares near 'bear case value'
05/24/21 Morgan Stanley
MorphoSys upgraded to Overweight from Equal Weight at Morgan Stanley
05/21/21 JPMorgan
MorphoSys price target lowered to EUR 105 from EUR 110 at JPMorgan
04/08/21 Deutsche Bank
MorphoSys price target lowered to EUR 116 from EUR 129 at Deutsche Bank
RPRX Royalty Pharma
$40.25 /

+0.09 (+0.22%)

11/09/20
Fly Intel: Top five analyst upgrades
11/09/20 UBS
Royalty Pharma upgraded to Buy from Neutral at UBS
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
07/13/20 Cowen
Cowen starts Royalty Pharma with Outperform, $55 price target
CNST Constellation Pharmaceuticals
$20.25 /

+0.43 (+2.17%)

01/25/21 BMO Capital
Constellation Pharmaceuticals upgraded to Outperform at BMO Capital
01/25/21 BMO Capital
Constellation upgraded to Outperform from Market Perform at BMO Capital
10/30/20 JPMorgan
Constellation added to Analyst Focus List at JPMorgan
09/08/20 Oppenheimer
Constellation Pharmaceuticals downgraded to Perform at Oppenheimer
RPRX Royalty Pharma
$40.25 /

+0.09 (+0.22%)

CNST Constellation Pharmaceuticals
$20.25 /

+0.43 (+2.17%)

  • 16
    Oct
  • 17
    Jun
  • 16
    Jun
Over a month ago
Conference/Events
Royalty Pharma participates in a conference call with Truist » 04:55
05/20/21
05/20
04:55
05/20/21
04:55
RPRX

Royalty Pharma

$39.96 /

-1.4 (-3.38%)

Conference call with CEO…

Conference call with CEO Legorreta will be held on May 20 hosted by Truist.

ShowHide Related Items >><<
RPRX Royalty Pharma
$39.96 /

-1.4 (-3.38%)

RPRX Royalty Pharma
$39.96 /

-1.4 (-3.38%)

11/09/20
Fly Intel: Top five analyst upgrades
11/09/20 UBS
Royalty Pharma upgraded to Buy from Neutral at UBS
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
07/13/20 Cowen
Cowen starts Royalty Pharma with Outperform, $55 price target
RPRX Royalty Pharma
$39.96 /

-1.4 (-3.38%)

  • 16
    Oct
  • 16
    Jun
Conference/Events
Royalty Pharma participates in a conference call with Truist » 11:10
05/14/21
05/14
11:10
05/14/21
11:10
RPRX

Royalty Pharma

$40.86 /

+0.68 (+1.69%)

Conference call with CEO…

Conference call with CEO Legorreta will be held on May 20 hosted by Truist.

ShowHide Related Items >><<
RPRX Royalty Pharma
$40.86 /

+0.68 (+1.69%)

RPRX Royalty Pharma
$40.86 /

+0.68 (+1.69%)

11/09/20
Fly Intel: Top five analyst upgrades
11/09/20 UBS
Royalty Pharma upgraded to Buy from Neutral at UBS
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
07/13/20 Cowen
Cowen starts Royalty Pharma with Outperform, $55 price target
RPRX Royalty Pharma
$40.86 /

+0.68 (+1.69%)

  • 16
    Oct
  • 16
    Jun
Earnings
Royalty Pharma raises FY21 adjusted cash receipt $1.94B-$1.98B from $1.78B-$1.8B » 07:13
05/11/21
05/11
07:13
05/11/21
07:13
RPRX

Royalty Pharma

$41.50 /

+0.535 (+1.31%)

Royalty Pharma now…

Royalty Pharma now anticipates full-year 2021 Adjusted Cash Receipts to be between $1.940B-$1.980B, excluding new transactions announced subsequent to the date of this release.

ShowHide Related Items >><<
RPRX Royalty Pharma
$41.50 /

+0.535 (+1.31%)

RPRX Royalty Pharma
$41.50 /

+0.535 (+1.31%)

11/09/20
Fly Intel: Top five analyst upgrades
11/09/20 UBS
Royalty Pharma upgraded to Buy from Neutral at UBS
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
07/13/20 Cowen
Cowen starts Royalty Pharma with Outperform, $55 price target
RPRX Royalty Pharma
$41.50 /

+0.535 (+1.31%)

  • 16
    Oct
  • 16
    Jun
Earnings
Royalty Pharma reports Q1 revenue $573M, consensus $509.7M » 07:10
05/11/21
05/11
07:10
05/11/21
07:10
RPRX

Royalty Pharma

$41.50 /

+0.535 (+1.31%)

Reports Q1 adjusted…

Reports Q1 adjusted EBITDA $482M, a 35% increase compared to Adjusted EBITDA of $356Min the first quarter of 2020. "Royalty Pharma continued its impressive business momentum," said Pablo Legorreta, Royalty Pharma founder and CEO. "We delivered outstanding top- and bottom-line growth in the first quarter of 2021 and expanded our portfolio of royalties on innovative medicines. Building off a landmark year in 2020, we announced nearly $800 million in new royalty acquisitions so far this year, spanning oncology, rare disease and neuroscience. In addition, we entered into an exciting collaboration with MSCI which leverages our deep scientific expertise and unique data analytics capabilities to create indexes that support investment in life sciences. We continue to be very excited about the growing role of royalty funding to advance health outcomes as well as the powerful dynamics in our business."

ShowHide Related Items >><<
RPRX Royalty Pharma
$41.50 /

+0.535 (+1.31%)

RPRX Royalty Pharma
$41.50 /

+0.535 (+1.31%)

11/09/20
Fly Intel: Top five analyst upgrades
11/09/20 UBS
Royalty Pharma upgraded to Buy from Neutral at UBS
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
07/13/20 Cowen
Cowen starts Royalty Pharma with Outperform, $55 price target
RPRX Royalty Pharma
$41.50 /

+0.535 (+1.31%)

  • 16
    Oct
  • 16
    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.